MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.41 B |
Market Cap[1] |
$ 576 B |
EBITDA (LTM) |
$ 9.42 B |
P/E (LTM) |
23.62 |
P/S (LTM) |
6.25 |
EPS (LTM) |
10.13 |
Johnson & Johnson is a multinational corporation that specializes in healthcare products, medical devices, and pharmaceuticals. Founded in 1886, the company has grown to become one of the largest healthcare companies in the world, with operations in over 60 countries.
The company's products are used by millions of people every day, from baby shampoo and band-aids to prescription drugs and surgical equipment. Some of its most well-known brands include Tylenol, Neutrogena, and Listerine.
Johnson & Johnson is committed to improving the health and well-being of people around the world. The company invests heavily in research and development, with a focus on finding new treatments for diseases such as cancer, Alzheimer's, and HIV/AIDS.
In addition to its healthcare products, Johnson & Johnson is also known for its commitment to corporate social responsibility. The company has a long history of supporting various charitable causes, including disaster relief efforts and global health initiatives.
Overall, is a trusted and respected leader in the healthcare industry, with a strong track record of innovation and social responsibility.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Amarin Corporation plc
AMRN
|
$ 14.67 | -0.07 % | $ 6.09 B | Nasdaq Global Market |  Irlanda |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Cabaletta Bio
CABA
|
$ 2.82 | 1.44 % | $ 283 M | Nasdaq Global Select Market | USA |
 |
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.29 | -3.01 % | $ 329 M | Nasdaq Global Select Market | Britain |
 |
CEL-SCI Corporation
CVM
|
$ 3.47 | -1.7 % | $ 221 M | NYSE American,SPB | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Denali Therapeutics
DNLI
|
$ 19.74 | -12.17 % | $ 3.25 B | Nasdaq Global Select Market,SPB | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | USA |
 |
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.09 | -9.17 % | $ 22.4 M | Nasdaq Capital Market | Israel |
 |
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Equillium
EQ
|
$ 2.06 | - | $ 118 M | Nasdaq Global Market | USA |
 |
Esperion Therapeutics
ESPR
|
$ 2.85 | 3.26 % | $ 592 M | Nasdaq Global Market,SPB | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 23.45 | -1.64 % | $ 631 M | Nasdaq Global Market | USA |
 |
China SXT Pharmaceuticals
SXTC
|
$ 1.32 | -5.2 % | $ 1.88 M | Nasdaq Global Select Market | China |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 47.55 | 0.98 % | $ 4.28 B | Nasdaq Global Market,SPB |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.45 | -1.77 % | $ 853 M | Nasdaq Global Select Market | Canada |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.